Printer Friendly

INAMED CORP. VOLUNTARILY SUSPENDS SHIPMENTS OF GEL-FILLED BREAST IMPLANTS

 INAMED CORP. VOLUNTARILY SUSPENDS SHIPMENTS
 OF GEL-FILLED BREAST IMPLANTS
 SANTA BARBARA, Calif., Jan. 7 /PRNewswire/ -- INAMED Corp. (NASDAQ: IMDC) today said that in compliance with a request for a moratorium on the sale of gel-filled breast implants announced by the U.S. Food and Drug Administration (FDA), the company's subsidiary, McGhan Medical Corp., has suspended shipments of the affected products pending further review or approval.
 INAMED President and Chairman Donald K. McGhan, stated that in addition to INAMED'S other business activities, the company has a strong position as a manufacturer of saline-filled (inflatable) mammary implants, which are not affected by the moratorium. Two of the three manufacturers of saline-filled mammary implants in the United States are subsidiaries of INAMED.
 The company's strategic planning for 1992 emphasizes the marketing and sales of saline-filled implants to achieve a leading worldwide market share. Manufacturing levels and product inventories were stepped-up during the second half of 1991 in order to address a projected increase in market demand for saline-filled mammary implants. The company's 1992 plan has been further enhanced by recent actions by the FDA relating to gel-filled mammary implants.
 "The FDA announcement will have an adverse effect on the company until such time as the gel-filled products are returned to the market or until sales of its saline-filled mammary implants achieve or exceed prior combined mammary implant levels of sales. The company expects this to be achieved in the first half of 1992."
 Further commenting on the FDA's announcement, INAMED's president said, "As we have continually stated and supported by data supplied in our Pre-Market Approval application (PMA), the company's gel- filled mammary implants are safe. We are confident that the FDA advisory panel, which is scheduled to re-convene within 45 days, will come to the same conclusion that they had in November -- namely that the gel-filled breast implants should remain on the market."
 In November 1991, after reviewing comprehensive data supplied by the company and three other manufacturers of gel-filled implants, the advisory panel unanimously recommended to the FDA that gel-filled implants remain on the market pending further study.
 INAMED Corp. is a medical device company which develops, manufactures and markets medical devices for the plastic and reconstructive, bariatric and general surgery markets. The company recently reported sales of over $31 million for the first nine months of 1991. Sales for 1990 were $35.7 million.
 -0- 1/7/92 R
 /CONTACT: Donald K. McGhan, chairman of INAMED, 805-684-6277; or Jimmy Caplan of Market Makers, 805-569-6919, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for INAMED/
 (IMDC) CO: INAMED Corp. ST: California IN: MTC SU:


AL-CH -- LA010 -- 7379 01/07/92 14:21 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1992
Words:441
Previous Article:CABOT MEDICAL ANNOUNCES RECORD QUARTER AND FISCAL YEAR END RESULTS; COMPANY ONCE AGAIN ATTAINS RECORD SALES AND EARNINGS
Next Article:PACIFIC TELECOM SUBSIDIARY COMPLETES MERGER WITH WAYSIDE TELCOM
Topics:


Related Articles
FDA PANEL RECOMMENDS BREAST IMPLANTS REMAIN ON THE MARKET
INAMED CORP. VOLUNTARILY SUSPENDS SHIPMENTS OF GEL-FILLED BREAST IMPLANTS
INAMED SUBSIDIARY HALTS SUIT FILED AGAINST FDA AND COMMISSIONER KESSLER
INAMED CORP. REPORTS RESULTS
FDA AUTHORIZES USE OF McGHAN BIODIMENSIONAL BREAST IMPLANTS UNDER URGENT NEED EXEMPTION
FDA panel backs silicone implants: long list of conditions.
FDA panel conditionally backs silicone implants: breast augmentation and reconstruction.
FDA raises bar for silicone breast implant approval: rejects advisory panel recommendation.
Comments of Sybil Goldrich, Executive Director of the Command Trust Network, on the FDA's 'Approvable Letter' to Inamed on Silicone Gel Breast...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters